主页 > 医学讨论 >
【medical-news】新药+依立替康：进展期NSCLC的希望
By Will Boggs, MD
NEW YORK (Reuters Health) Aug 22 - The combination of the oral fluoropyrimidine formulation S-1 and irinotecan may lengthen survival with acceptable toxicity in patients with advanced non-small-cell lung cancer (NSCLC), according to investigators in Japan.
"Given its efficacy and favorable toxicity profile, S-1-containing non-platinum regimens are promising alternatives for the treatment of advanced NSCLC and warrant further evaluation in randomized trials," Dr. Isamu Okamoto from Kinki University School of Medicine, Osaka, told Reuters Health.
In a phase II trial, Dr. Okamoto and colleagues investigated the safety and efficacy of the S-1 plus irinotecan combination in 56 patients with previously untreated advanced NSCLC. The findings are reported in the August 15th issue of Clinical Cancer Research.
Sixteen patients (28.6%) achieved partial responses to the combination regimen, the authors report, but no patients had a complete response. Twenty-four patients (42.9%) had stable disease, and 12 patients (21.4%) had disease progression.
The median progression-free survival was 4.9 months and the median overall survival was 15 months, the report indicates, with an estimated 1-year survival rate of 63%.
Dose reductions were necessary in only eight treatment cycles, which was caused by diarrhea in three patients, anorexia in two patients, vomiting in two patients, and an increase in serum ALT and AST levels in one patient.
Treatment was discontinued because of toxicity in two patients (one for grade 3 pneumonitis and one for prolonged grade 3 anorexia and fatigue), the investigators note, and there were no treatment-related deaths.
"We are currently conducting a randomized phase III trial comparing carboplatin plus S-1 with carboplatin and paclitaxel for chemo-naive advanced NSCLC," the researchers note.
"The patient accrual has been already completed. The final results would be next summer," Dr. Okamoto added.
Clin Cancer Res 2008;14:5250-5254.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-07 17:11
医学,生命科学网